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T
he fifth International Congress on Rare Pulmonary
Diseases and Orphan Drugs will take place in Milan,
Italy, on February 8–9, 2013 (www.pulmonaryrarediseases.
com). 10 yrs have passed since the first Congress was held. Since
then, the Congress has taken place regularly every 2 yrs, with
growing success and ever increasing numbers of participants and
speakers from around the world. The International Congress on
Rare Pulmonary Diseases and Orphan Drugs is the only European
event dedicated to different types of rare pulmonary diseases
affecting both parenchymal and vascular structures. Overall, more
than 150 speakers and 650 participants have attended the past
four Congresses, where scientific programmes are designed to
build bridges between physicians specialised in the management
of different lung disorders that have the common feature of being
rare diseases, i.e.with prevalence lower than one per 2,000 persons
according to the European definition.
Proceedings from the 2005 and 2009 Congresses have been
published previously elsewhere [1, 2]. In the present issue of the
European Respiratory Review (ERR), three selected articles focus on
some of the most important and widely discussed topics from
the fourth Congress held on February 25–26, 2011 [3–5]. These
manuscripts summarise the two main scientific areas of discus-
sion: 1) the basic science research, and 2) the prognostic evaluation
and management of pulmonary vascular and interstitial lung
diseases. In addition, several other important topics were dis-
cussed during the 2-day Congress, including original scientific
data and results of clinical trials with new drugs that provided
evidence for innovative therapeutic approaches to rare pulmon-
ary diseases. New developments in the treatment of pulmonary
arterial hypertension (PAH), and critical issues on idiopathic
pulmonary fibrosis (IPF), sarcoidosis, rheumatoid arthritis, lung
involvement in systemic sclerosis, pulmonary Langerhans’ cells
histiocytosis and lymphangioleiomyomatosis (LAM) were exten-
sively discussed by outstanding international speakers.
The three papers published in this issue of the ERR illustrate
the different clinical and translational issues that were presented
and discussed at the Congress. CAMINATI et al. [3] propose and
discuss a multidisciplinary and integrated approach to smoking-
related interstitial lung diseases, O’CALLAGHAN and HUMBERT [4]
delineate the critical issues in the evaluation of survival in
patients with PAH and, finally, GLASGOW et al. [5] review the
multiple aspects of lymphatic involvement of LAM and IPF.
In recent years, the interest for rare diseases has grown
throughout the entire medical community, and many respiratory
physicians were pioneers in this field of medicine. Data clearly
demonstrate this emerging awareness: in 1989–1999 a total of
114 patients were enrolled in four well-conducted IPF studies,
whereas in the following decade (2000–2010) almost 3,000
patients were enrolled in a total of 11 studies [6]. A search of
articles written in English in PubMed with the keywords
‘‘idiopathic pulmonary fibrosis’’ ‘‘lymphangioleiomyomatosis’’
and ‘‘pulmonary Largerhans’ cells histiocytosis’’ shows a grow-
ing numbers of papers published in recent years (table 1), while
the search for rare pulmonary disease studies in the Clinical-
trials.gov website retrieved a total of 114 trials on IPF and 18 on
LAM. If we consider the rarity of these diseases and the state-of-
the-art research just a few years ago, these data represent a
substantial (and astonishing) number of clinical studies.
However, by far the paradigm for success of the research in
this field and in the development of orphan drugs is PAH. This
disease has greatly benefited from the establishment of an
international network of research focused on understanding
the complex pathogenesis and development of the disease. The
registration of eight different drugs, with important impact on
the prognosis as well as the quality of life of patients suffering
from this disease, demonstrates the strong effort made in the
last 20 yrs to help clinicians, patients and relatives fight this
devastating pulmonary vascular disease.
The tremendous progress made in the field of rare pulmonary
diseases has been made possible by a number of factors
including, among others: 1) better delineation of some of these
diseases (especially IPF); 2) the collective research effort by
the respiratory community; 3) the clinical research effort of
collaborative groups, such as the Groupe d’Etudes et de
Recherche sur les Maladies ‘‘Orphelines’’ Pulmonaires [7];
4) the tremendous effort of the public, physicians and patients,
and the progress in the terminology of rare diseases by
Orphanet (www.orpha.net); 5) the emergence of coordinated
action against rare diseases by health authorities in several
western countries and at European level; 6) the role of patient
associations, which have raised awareness, money and, in
some cases, facilitated clinical trials [8]; and 7) the investment
by major pharmaceutical companies, themselves fostered by
orphan drug legislation.
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During the 2011 European Respiratory Society Congress in
Amsterdam, the Clinical Assembly of the society organised a
symposium dedicated to these topics, the proceeding of which
were published in the European Respiratory Journal [9]. The
increasing interest of the ERR in this field is also reflected by
the 23 articles published on IPF since 2005, and the 31 articles
on PAH and three on LAM published in the last 2 yrs.
The decision of the ERR to publish these reports from the 4th
International Congress on Rare Pulmonary Diseases and Orphan
Drugs goes further in this direction, highlighting that rare diseases
represent an important field of medicine not only for pulmonol-
ogists who are skilled in diagnosing and treating particular
groups of these illnesses, but for all respiratory physicians.
Knowledge exchange and dissemination among experts on
different areas of clinical and basic research in respiratory
medicine, with different specialised pulmonary medicine exper-
tise (from vascular to interstitial lung diseases), is part of the
stimulating challenge of providing new insights into science and
clinical care, thus helping patients and supporting doctors.
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TABLE 1 PubMed search results
Keywords 1980–1989 1990–1999 2000–2009 2010–May 2012
Idiopathic pulmonary fibrosis 249 577 1577 770
Lymphangioleiomyomatosis 39 170 472 163
Pulmonary Langerhans’ cell histiocytosis 142 201 291 74
EDITORIAL: RARE AND ORPHAN DISEASES S. HARARI ET AL.
172 VOLUME 21 NUMBER 125 EUROPEAN RESPIRATORY REVIEW
